$RIGL
RIGEL PHARMACEUTICALS INC
Runway:cash-flow +
NasdaqMarket cap: —CIK 0001034842
Upcoming catalysts
1 surfacedDrug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06161974 | Olutasidenib + TMZ | Phase 2 | Recruiting | 2029-06-01 |
| NCT07486713 | olutasidenib | Phase 4 | Recruiting | 2027-04-30 |
| NCT05308264 | R906289 Monosodium (R289 Na) | Phase 2 | Recruiting | 2026-08-01 |
| NCT04138927 | Fostamatinib disodium | Phase 3 | Enrolling By Invitation | 2024-04-01 |
| NCT04904276 | Fostamatinib | — | Terminated | 2022-11-17 |
| NCT04629703 | Fostamatinib | Phase 3 | Completed | 2022-09-05 |
| NCT03764618 | Fostamatinib disodium | Phase 3 | Completed | 2022-04-11 |
| NCT02077192 | Fostamatinib disodium | Phase 3 | Completed | 2020-06-02 |
| NCT02612558 | Fostamatinib 150 mg bid | Phase 2 | Completed | 2019-12-01 |
| NCT02112838 | Fostamatinib 150 mg | Phase 2 | Completed | 2018-03-23 |
| NCT02076412 | Fostamatinib disodium | Phase 3 | Completed | 2016-08-01 |
| NCT02040623 | R348 Ophthalmic Solution, 0.2% | Phase 2 | Completed | 2016-07-01 |
| NCT02076399 | Fostamatinib disodium | Phase 3 | Completed | 2016-04-21 |
| NCT02433236 | Fostamatinib Disodium tablet 100 mg | Phase 2 | Withdrawn | 2015-09-01 |
| NCT01900249 | R348 Ophthalmic Solution, 0.2% | Phase 2 | Completed | 2014-07-01 |
| NCT01597050 | R932333 | Phase 2 | Completed | 2013-09-01 |
| NCT01591044 | Placebo | Phase 2 | Completed | 2013-07-01 |
| NCT01733992 | R348 Ophthalmic Solution, 0.2% | Phase 1 | Completed | 2013-02-01 |
| NCT00798096 | Fostamatinib disodium | Phase 2 | Completed | 2010-04-01 |
| NCT00706342 | Fostamatinib Disodium / R935788 | Phase 2 | Completed | 2010-04-01 |